- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Implants of leuprorelin.
Carcinoma - prostate
Treatment of hormone-dependent, advanced prostate cancer.
Treatment of high risk, localised and locally advanced, hormone-dependent prostate cancer in combination with radiotherapy.
1 implant once every 3 months.
For abdominal subcutaneous injection.
Children under 18 years
Long QT syndrome
Torsade de pointes
Precautions and Warnings
Family history of long QT syndrome
Predisposition to diabetes mellitus
Predisposition to seizures
History of depression
History of seizures
History of torsade de pointes
Spinal cord compression
Correct electrolyte disorders before treatment
Advise ability to drive/operate machinery may be affected by side effects
Consider anti-androgen treatment to prevent initial testosterone increase
Prostate cancer: Prophylaxis of flare with anti-androgen is recommended
Monitor testosterone levels at baseline and periodically during treatment
Perform digital rectal examination & PSA prior to and following treatment
Consider monitoring ECG in patients at risk of QT prolongation
If spinal cord compression present/develops,use specific standard treatment
Monitor blood glucose closely in patients with diabetes mellitus
Monitor hepatic function
Monitor patient for signs and symptoms of depression
Monitor patients with brain metastases for the first few weeks of therapy
Monitor patients with metabolic disorders
Monitor patients with pre-existing hypertension
Monitor patients with urinary obstruction for the first weeks of therapy
Monitor serum electrolytes
Monitor testosterone level in event of injection site abscess
Advise patient to report any new or worsening depression/suicidal ideation
Advise patient to report sudden headache, vomiting or visual disturbances
Pregnancy and Lactation
Not indicated for use in women.
Not indicated for use in women.
Blood glucose disturbances
Blood lipid changes
Blood pressure changes
Decrease in bone mineral density
Dry mucous membranes
Erythema at injection site
Increases in hepatic enzymes
Injection site reactions
Interstitial lung disease
Local pain (injection site)
Oedema (injection site)
Prolongation of QT interval
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: January 2020
Summary of Product Characteristics: Staladex 10.72mg Implant. Typharm Limited. Revised October 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.